- Home
- BEAM vs BDJ Comparison
BEAM vs BDJ Comparison
Compare BEAM & BDJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- BDJ
- Stock Information
- Founded
- BEAM 2017
- BDJ 2005
- Country
- BEAM United States
- BDJ United States
- Employees
- BEAM N/A
- BDJ N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- BDJ Finance Companies
- Sector
- BEAM Health Care
- BDJ Finance
- Exchange
- BEAM Nasdaq
- BDJ Nasdaq
- Market Cap
- BEAM 1.8B
- BDJ 1.5B
- IPO Year
- BEAM 2020
- BDJ N/A
- Fundamental
- Price
- BEAM $16.19
- BDJ $8.59
- Analyst Decision
- BEAM Strong Buy
- BDJ
- Analyst Count
- BEAM 11
- BDJ 0
- Target Price
- BEAM $48.90
- BDJ N/A
- AVG Volume (30 Days)
- BEAM 1.9M
- BDJ 561.6K
- Earning Date
- BEAM 05-06-2025
- BDJ 01-01-0001
- Dividend Yield
- BEAM N/A
- BDJ 8.85%
- EPS Growth
- BEAM N/A
- BDJ N/A
- EPS
- BEAM N/A
- BDJ N/A
- Revenue
- BEAM $63,578,000.00
- BDJ N/A
- Revenue This Year
- BEAM N/A
- BDJ N/A
- Revenue Next Year
- BEAM $10.59
- BDJ N/A
- P/E Ratio
- BEAM N/A
- BDJ N/A
- Revenue Growth
- BEAM N/A
- BDJ N/A
- 52 Week Low
- BEAM $13.53
- BDJ $6.91
- 52 Week High
- BEAM $35.25
- BDJ $8.66
- Technical
- Relative Strength Index (RSI)
- BEAM 39.35
- BDJ 56.48
- Support Level
- BEAM $15.35
- BDJ $8.47
- Resistance Level
- BEAM $17.47
- BDJ $8.63
- Average True Range (ATR)
- BEAM 0.90
- BDJ 0.09
- MACD
- BEAM -0.07
- BDJ -0.00
- Stochastic Oscillator
- BEAM 24.71
- BDJ 60.29
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.